AeroRx Therapeutics, Inc.
AeroRx Therapeutics is developing potential best-in-class nebulized combination therapies to improve COPD treatment.
Funding history
About AeroRx Therapeutics, Inc.
How much funding has AeroRx Therapeutics, Inc. raised?
AeroRx Therapeutics, Inc. has raised $10.4M in total funding. The most recent round was Series A.
Where is AeroRx Therapeutics, Inc. headquartered?
AeroRx Therapeutics, Inc. is headquartered in La Jolla, CA.
What does AeroRx Therapeutics, Inc. do?
AeroRx Therapeutics is developing potential best-in-class nebulized combination therapies to improve COPD treatment.
What problem does AeroRx Therapeutics, Inc. solve?
Many COPD patients, especially older and sicker ones on inhaled LABA/LAMA therapy, don't get optimal benefit and continue to experience symptoms.
What's AeroRx Therapeutics, Inc.'s solution?
AeroRx is a clinical-stage biopharmaceutical company developing nebulized combination COPD treatments as an alternative to inhalers for moderate-to-severe patients.
What makes AeroRx Therapeutics, Inc. different?
Combines LAMA and LABA therapies into a fixed-dose solution formulation for nebulization, with a further fixed-dose triple combination in development that adds an anti-inflammatory for patients who also need bronchodilator therapy.
What makes AeroRx Therapeutics, Inc. notable?
AeroRx Therapeutics closed a $21M Series A round led by Avalon BioVentures, with Alexandria Venture Investments and Correlation Ventures among its backers, to advance a nebulized COPD therapy.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.